Home > Companies > Cannamedical® Pharma GmbH

Cannamedical® Pharma GmbH

cannamedical.com

Cannamedical® Pharma GmbH has a pharmaceutical wholesale licence in accordance with 52a of the Medicines Act (AMG) and a permit to handle narcotics in accordance with § 3 of the Act on Narcotics (BtMG). As the only independent German cannabis wholesaler we cooperate with several selected international producers. Our independence guarantees a qualitatively and quantitatively unique range of medical cannabis on the German market. In addition to our independence we were also one of the first companies that received the license to import cannabis to Europe. As the laws in Germany only changed in March 2017, making medical cannabis legal, we were one of the very first to deal with the authorities and have since obtained 7 different licenses, allowing us to import from any GMP production in the world. Thus we are one of the pioneers in the European cannabis industry and have become specialists in GMP processing and authority auditing. With our strong team, we are committed to act responsibly and ethically at all times. We fulfill our social responsibility and tasks with passion and dedication. Our clear focus lies on ensuring the adequate supply of medical care for patients, providing information within a professional framework and satisfying our customers.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

National Medtech & Biotech Summit 2024

Conference

Related News

Business Insights

RECRO ANNOUNCES ACQUISITION OF SAN DIEGO-BASED IRISYS, CREATING BI-COASTAL, FULL SERVICE CDMO

Recro Pharma, Inc. | August 16, 2021

Recro Pharma, Inc. a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced its acquisition of IRISYS, a San Diego-based CDMO that possesses capabilities that complement and expand those of Recro. Recro acquired IRISYS for approximately $50 million in a combination of cash, shares of Recro common stock and a seller promissory note. With its acquisition of IRI...

Business Insights

INNOTECH AND OSARO COLLABORATE TO BUILD A DEMONSTRATION AI PICKING ROBOT SYSTEM FOR ROHTO PHARMACEUTICAL’S NEXT-GENERATION SMART FACTORY

INNOTECH and OSARO | January 12, 2022

OSARO Inc. a global leader in the development and provision of advanced robotics automation, and INNOTECH CORPORATION, which provides advanced products for electronics and consumer industries, have announced a collaboration to create an innovative demonstration for Rohto Pharmaceutical Co., Ltd. using AI piece-picking robots. The two companies are jointly providing picking robots and jointly building a system for their introduction into a new factory production line, scheduled for completion in ...

Business Insights

BC PLATFORMS PARTNERS WITH EU FUNDED, AI-DRIVEN, CANCER DATA INITIATIVE

BC Platforms | November 25, 2022

BC Platforms a global leader in healthcare data management and analytics announced that it has been chosen as key partner in a European Commission project. Under the EC's Horizon Europe program*, Helsinki University Hospital has been awarded a contract to lead a EURO 7 million consortium project termed ONCOVALUE. BCP will work closely with HUS as a key delivery partner in this major EC project. ONCOVALUE is an Artificial Intelligence-based framework which assesses, in real-tim...

Business Insights

ITM RECEIVES EQUITY INVESTMENT OF EUR 25 MILLION FROM STRATEGIC PARTNER GRAND PHARMA

ITM Isotope Technologies Munich SE | February 17, 2022

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Grand Pharmaceutical Group Limited (GP), a diversified global pharmaceutical company listed in Hong Kong, today announced that ITM and a subsidiary of GP have entered into a definitive agreement under which GP will make a EUR 25 million (USD 28 million) equity investment in ITM. The agreement will further deepen the strategic collaboration between the two companies and support ITM to further expanding its...

Business Insights